IOMX

IOMX

Registrada

Nominativa · Brasil

Outros setoresSoftware e TI

Marca registrada: vale avaliar o risco de conflito

A marca "IOMX" está registrada no Brasil. Se você usa ou pretende usar um nome similar, pode haver risco de conflito. Vale olhar classes, histórico e despachos antes de decidir o próximo passo.

Panorama da marca

Situação INPI
Concessão de registro em designação
Tramitação até registro
1 ano e 4 meses
Eventos no processo
3
Última atualização
28 de abril de 2026

Dados do processo

Titular
iOmx Therapeutics AG
Número do processo
501845424
Número de registro
501845424
Natureza
Madri Produto/Serviço
Data do depósito
18 de dezembro de 2024
Data do registro
28 de abril de 2026
Válido até
18 de dezembro de 2034

Produtos e serviços cobertos

Classe 1Outros setores

Chemical preparations for scientific and industrial purposes; genetically engineered polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular artificial polypeptides and proteins and nucleic acid coding for these; diagnostic preparations, except for medical or veterinary use.;

Classe 5Outros setores

Pharmaceuticals, medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and/or disorders in humans and/or animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic or central nervous system diseases, complaints and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment or prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic or central nervous system diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders.;

Classe 42Software e TI

Scientific services and research relating thereto; scientific services and research relating to biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and/or medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and/or diagnostic apparatus; conducting evaluations in the field of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; cancer diagnostics for scientific purposes; services of a biological or biochemical laboratory; biological and biochemical examination services; providing technical and scientific information about a biotechnology company, its technologies, projects, product-candidates, products and/or services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus.;

Linha do tempo do processo

3 eventos

Movimentações mais recentes da marca “IOMX” publicadas na Revista da Propriedade Industrial (RPI). O detalhe de cada despacho fica na consulta completa.

  1. Concessão / deferimento28 de abr. de 2026RPI 2886

    Concessão de registro em designação

    Detalhes na consulta completa
  2. Andamento14 de abr. de 2026RPI 2884

    Deferimento de designação

    Detalhes na consulta completa
  3. Ação / prazo08 de jul. de 2025RPI 2844

    Publicação de pedido de registro para oposição (exame formal de designação concluído)

    Detalhes na consulta completa

O que fazer se a sua marca se aproxima de "IOMX"?

Conflitos de marcas no Brasil são resolvidos com base na anterioridade do depósito, nas classes de Nice e no segmento de atuação. O processo tem várias fases e pode ficar complexo quando o nome é parecido ou o mercado se cruza. Uma leitura cuidadosa ajuda a decidir se vale seguir, ajustar ou recuar.

A TrademarkIQ cruza histórico, decisões e padrões de aprovação por classe e setor em uma base com +6 milhões de processos brasileiros. Isso ajuda a enxergar o risco com mais contexto e a encontrar o melhor caminho comercial e jurídico para a sua marca.

Vigilância de marca

Seja avisado antes que vire problema

Monitoramento contínuo: receba um alerta a cada novo depósito que possa colidir com IOMX ou com a sua marca — a tempo de se opor dentro do prazo.

Monitorar marca

Dados actualizados a partir de uma base com +6 milhões de marcas brasileiras analisadas. Esta página é informativa e não substitui parecer jurídico, mas ajuda a orientar a decisão com mais contexto comercial e técnico.